TME Pharma N.V.
Clinical-stage biotech targeting the tumor microenvironment for aggressive cancers.
ALTME | Euronext Growth
Overview
Corporate Details
- ISIN(s):
- NL0015000YE1 (+1 more)
- LEI:
- 724500EPNADXWZ58U595
- Country:
- Germany
- Address:
- Max-Dohrn-Strasse 8-10, 10589 Berlijn
- Website:
- https://www.tmepharma.com/
- Sector:
- Manufacturing
Description
TME Pharma N.V. is a clinical-stage biotechnology company developing novel therapies for aggressive cancers by targeting the tumor microenvironment (TME). The company's proprietary technology focuses on neutralizing chemokines within the TME to break down the tumor's protective barriers and inhibit its repair mechanisms. This approach is designed to work in combination with other treatments, such as radiotherapy and immunotherapy, to enhance their therapeutic impact. TME Pharma's lead clinical programs are concentrated on difficult-to-treat cancers, including glioblastoma and pancreatic cancer. Its lead candidate, NOX-A12, has shown promising results in clinical trials for glioblastoma, demonstrating a statistically significant improvement in patient survival when combined with standard-of-care therapies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-06-28 08:00 |
Informations privilégiées / Autres communiqués
|
French | 234.6 KB | ||
| 2024-06-27 18:00 |
Inside Information / Other news releases
|
English | 310.9 KB | ||
| 2024-06-27 18:00 |
Informations privilégiées / Autres communiqués
|
French | 327.4 KB | ||
| 2024-06-18 08:00 |
Inside Information / Other news releases
|
English | 237.5 KB | ||
| 2024-06-18 08:00 |
Informations privilégiées / Autres communiqués
|
French | 248.4 KB | ||
| 2024-06-17 18:40 |
Inside Information / Other news releases
|
English | 345.0 KB | ||
| 2024-06-17 18:40 |
Informations privilégiées / Autres communiqués
|
French | 352.2 KB | ||
| 2024-06-17 17:35 |
Inside Information / Other news releases
|
English | 236.7 KB | ||
| 2024-06-17 17:35 |
Informations privilégiées / Autres communiqués
|
French | 259.0 KB | ||
| 2024-05-27 08:00 |
Terms of availability of the preparatory documents for the GM
|
English | 262.0 KB | ||
| 2024-05-27 08:00 |
Modalités de mise à disposition des documents préparatoires à l'AG
|
French | 280.3 KB | ||
| 2024-04-25 18:00 |
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 268.3 KB | ||
| 2024-04-25 18:00 |
Inside Information / News release on accounts, results
|
English | 255.3 KB | ||
| 2024-04-23 08:00 |
Inside Information / Other news releases
|
English | 238.5 KB | ||
| 2024-04-23 08:00 |
Informations privilégiées / Autres communiqués
|
French | 251.1 KB |
Automate Your Workflow. Get a real-time feed of all TME Pharma N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for TME Pharma N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for TME Pharma N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
